Compare Keysight Technologies Inc (KEYS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Sanofi SA — how do they compare? Keysight Technologies Inc trades at $353.84 (market cap $58.74B), while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays a 5.55% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| KEYS | SNY | |
|---|---|---|
Market Cap | $58.74B | $104.30B |
Sector | Technology | Health |
52-Week High | $373.34 | $52.34 |
52-Week Low | $158.51 | $41.33 |
Enterprise Value | $59.08B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $353.23, up 5.31% over the past day and showing strong momentum. The stock is in a bullish technical trend, with recent earnings consistently beating estimates. Revenue for 2025 was $5.38 billion, with a net income margin of 17.31%, and the company has announced strategic collaborations and product launches in 2026, including advancements in 5G and photonics design.
The outlook for KEYS is positive, supported by robust earnings performance and analyst optimism, with an average price target of $396.56. Key risks include high valuation multiples and significant capital expenditure trends. Upside potential hinges on continued execution and market adoption of new technologies.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
